Payment overview · 2025
General Payments
$360.43
14 reported records · 8 companies
Healthcare provider profile · identity verified
John B Calhoun, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLESTON, SC · NPI 1770845141
Verified facts
What the public records show
CMS Open Payments records show John B Calhoun, M.D. received $360.43 in general payments during 2025 across 14 reported records.
ABIOMED accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $114.93 | 31.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $83.59 | 23.2% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$59.46 | 16.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.03 | 10.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.71 | 5.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.19 | 4.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.38 | 4.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.14 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.43 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $59.46 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.98 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 713 | 229 |
| Amlodipine Besylate | Amlodipine Besylate | 683 | 198 |
| Gabapentin | Gabapentin | 556 | 114 |
| Tramadol Hcl | Tramadol Hcl | 520 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 441 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 410 | 142 |
| Losartan Potassium | Losartan Potassium | 408 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 382 | 96 |
| Trazodone Hcl | Trazodone Hcl | 348 | 84 |
| Lisinopril | Lisinopril | 336 | 100 |
| Alprazolam | Alprazolam | 314 | 50 |
| Metformin Hcl | Metformin Hcl | 248 | 72 |
| Furosemide | Furosemide | 241 | 78 |
| Meloxicam | Meloxicam | 237 | 69 |
| Sertraline Hcl | Sertraline Hcl | 236 | 65 |
| Mounjaro | Tirzepatide | 224 | 43 |
| Omeprazole | Omeprazole | 218 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 191 | 75 |
| Potassium Chloride | Potassium Chloride | 183 | 55 |
| Eliquis | Apixaban | 176 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 43 |
| Montelukast Sodium | Montelukast Sodium | 161 | 54 |
| Donepezil Hcl | Donepezil Hcl | 154 | 38 |
| Clonazepam | Clonazepam | 151 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 45 |
| Memantine Hcl | Memantine Hcl | 149 | 29 |
| Metformin Hcl Er | Metformin Hcl | 145 | 46 |
| Simvastatin | Simvastatin | 142 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 40 |
| Carvedilol | Carvedilol | 130 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 38 |
| Ezetimibe | Ezetimibe | 121 | 36 |
| Buspirone Hcl | Buspirone Hcl | 115 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 28 |
| Alendronate Sodium | Alendronate Sodium | 113 | 36 |
| Methocarbamol | Methocarbamol | 112 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 36 |
| Bupropion Xl | Bupropion Hcl | 107 | 26 |
| Allopurinol | Allopurinol | 105 | 29 |
| Chlorthalidone | Chlorthalidone | 104 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 22 |
| Pregabalin | Pregabalin | 99 | 23 |
| Famotidine | Famotidine | 96 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 20 |
| Lorazepam | Lorazepam | 95 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 35 |
| Januvia | Sitagliptin Phosphate | 89 | 23 |
| Nifedipine Er | Nifedipine | 87 | 26 |
| Ozempic | Semaglutide | 84 | 19 |
| Eszopiclone | Eszopiclone | 82 | 14 |
| Glimepiride | Glimepiride | 82 | 21 |
| Spironolactone | Spironolactone | 77 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 17 |
| Mirtazapine | Mirtazapine | 69 | 18 |
| Glipizide Er | Glipizide | 66 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 13 |
| Jardiance | Empagliflozin | 57 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 18 |
| Bumetanide | Bumetanide | 55 | 18 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 18 |
| Valsartan | Valsartan | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 12 |
| Temazepam | Temazepam | 47 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Baclofen | Baclofen | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 37 |
| Ondansetron Odt | Ondansetron | 40 | 23 |
| Clonidine Hcl | Clonidine Hcl | 39 | 18 |
| Glipizide | Glipizide | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 15 |
| Atenolol | Atenolol | 36 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 26 |
| Estradiol | Estradiol | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Colchicine | Colchicine | 30 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 20 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Rivastigmine | Rivastigmine | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Nystatin | Nystatin | 27 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 25 |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 23 |
| Megestrol Acetate | Megestrol Acetate | 25 | 13 |
| Risperidone | Risperidone | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 24 |
| Finasteride | Finasteride | 24 | 11 |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 14 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Belsomra | Suvorexant | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Prednisone | Prednisone | 19 | 12 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alprazolam Er | Alprazolam | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Zonisamide | Zonisamide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.43 · 14 records | ABIOMED | AIRSUPRA, Dexcom G6 Transmitter, EVENITY, INSPIRE, REPATHA, REXULTI, SYMPLICITY G3, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error